[1]杨晴 梁岩.利伐沙班预防血栓的研究进展[J].心血管病学进展,2022,(10):932.[doi:10.16806/j.cnki.issn.1004-3934.2022.10.016]
　YANG Qing,LIANG Yan.Rivaroxaban in The Prevention of Thrombosis[J].Advances in Cardiovascular Diseases,2022,(10):932.[doi:10.16806/j.cnki.issn.1004-3934.2022.10.016]
点击复制

利伐沙班预防血栓的研究进展()
分享到：

《心血管病学进展》[ISSN:51-1187/R/CN:1004-3934]

卷:
期数:
2022年10期
页码:
932
栏目:
综述
出版日期:
2022-10-25

文章信息/Info

Title:
Rivaroxaban in The Prevention of Thrombosis
作者:
杨晴 梁岩
(中国医学科学院 北京协和医学院 国家心血管病中心阜外医院急诊中心,北京100037)
Author(s):
YANG Qing; LIANG Yan
(Emergency Center,Fuwai Hospital,National Center for Cardiovascular Diseases,Chinese Academy of Medical Sciences and Peking Union Medical College,Beijing 100037,China)
关键词:
利伐沙班; 血栓预防; 静脉血栓栓塞症
Keywords:
Rivaroxaban;  Prevention of thrombosis;  Venous thromboembolism
DOI:
10.16806/j.cnki.issn.1004-3934.2022.10.016
摘要:
以利伐沙班为代表的直接口服抗凝药逐渐在心血管疾病、骨外科及急重症等诸多领域取得不错的疗效成果。和传统口服抗凝药相比，利伐沙班有其特有的优势，如稳定可依赖的药代动力学、不需频繁的实验室监测等。除应用于非瓣膜性心房颤动的卒中预防以及静脉血栓栓塞症的二级预防，利伐沙班对于其他疾病相关性血栓及栓塞事件的预防作用还有待于更多循证医学证据支持。根据血栓的形成机制的不同，本文将从静脉系统血栓、动脉系统血栓以及心腔内血栓三个部分论述利伐沙班作为预防用药的研究进展。
Abstract:
Direct oral anticoagulants,represented by rivaroxaban,have been gradually achieved remarkable results in numerous areas such as cardiovascular diseases,major orthopaedic surgery and emerging diseases. Compared with classic oral anticoagulants,rivaroxaban has its unique advantages,such as stable and reliable pharmacokinetics with no need for frequent laboratory monitoring. Besides for stroke prevention in patients with non-valvular atrial fibrillation and for secondary prevention of venous thromboembolism ,more evidence is required to explore the value of rivaroxaban in the prevention of other thromboembolic events. According to the different mechanisms of thrombosis ,the paper reviews the research progress of rivaroxaban as a prophylactic agent in three sections:venous thrombosis,arterial thrombosis and intracardiac thrombosis.

参考文献/References:

[1] Pudusseri A,Shameem R,Spyropoulos AC. A new paradigm shift in antithrombotic therapy[J]. Front Pharmacol,2013,4:133.

[2] Falck-Ytter Y,Francis CW,Johanson NA,et al. Prevention of VTE in orthopedic surgery patients: Antithrombotic Therapy and Prevention of Thrombosis,9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines[J]. Chest,2012,141(2 Suppl):e278S-e325S.

[3] Schulman S,Goldhaber SZ,Kearon C,et al. Treatment with dabigatran or warfarin in patients with venous thromboembolism and cancer[J]. Thromb Haemost,2015,114(1):150-157.

[4] Poudel SK,Park DY,Jia X,et al. Clinical outcomes of isolated distal deep vein thrombosis versus proximal venous thromboembolism in cancer patients: The Cleveland Clinic experience[J]. J Thromb Haemost,2020,18(3):651-659.

[5] Hummert SE,Gilreath J,Rodgers GM,et al. Comparative evaluation of the safety and effectiveness of rivaroxaban (riva) and enoxaparin (enox) for treatment of venous thromboembolism (VTE) in cancer patients[J]. J Clin Oncol,2017,35(15_suppl):e18268-e18268.

[6] Bauersachs R,Berkowitz SD,Brenner B,et al. Oral rivaroxaban for symptomatic venous thromboembolism[J]. N Engl J Med,2010,363(26):2499-2510.

[7] Buller HR. Once-daily oral rivaroxaban versus placebo in the long-term prevention of recurrent symptomatic venous thromboembolism. The Einstein-Extension study[J]. Blood,2009,114(22):LBA-2.

[8] Büller HR,Prins MH,Lensin AW,et al. Oral rivaroxaban for the treatment of symptomatic pulmonary embolism[J]. N Engl J Med,2012,366(14):1287-1297.

[9] Steffel J,Collins R,Antz M,et al. 2021 European Heart Rhythm Association Practical Guide on the use of non-vitamin k antagonist oral anticoagulants in patients with atrial fibrillation[J]. Europace,2021,23(10):1612-1676.

[10] Mega JL,Braunwald E,Wiviott SD,et al. Rivaroxaban in patients with a recent acute coronary syndrome[J]. N Engl J Med,2012,366(1):9-19.

[11] Eikelboom JW,Connolly SJ,Bosch J,et al. Rivaroxaban with or without aspirin in stable cardiovascular disease[J]. N Engl J Med,2017,377(14):1319-1330.

[12] Zhang Z,Si D,Zhang Q,et al. Prophylactic rivaroxaban therapy for?left ventricular thrombus after anterior ST-segment elevation myocardial infarction[J]. JACC Cardiovasc Interv,2022,15(8):861-872.

[13] Barnes GD,Burnett A,Allen A,et al. Thromboembolic prevention and anticoagulant therapy during the COVID-19 pandemic: updated clinical guidance from the anticoagulation forum[J]. J Thromb Thrombolysis,2022,54(2):197-210.

[14] Tun NM,Oo TH. Prevention and treatment of venous thromboembolism with new oral anticoagulants: a practical update for clinicians[J]. Thrombosis,2013,2013:183616.

[15] Konstantinides SV,Meyer G,Becattini C,et al. 2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS)[J]. Eur Heart J,2020,41(4):543-603.

[16] Weitz JI,Lensing AWA,Prins MH,et al. Rivaroxaban or aspirin for extended treatment of venous thromboembolism[J]. N Engl J Med,2017,376(13):1211-1222.

[17] Hart RG,Sharma M,Mundl H,et al. Rivaroxaban for stroke prevention after embolic stroke of undetermined source[J]. N Engl J Med,2018,378(23):2191-2201.

[18] Merkler AE,Pearce LA,Kasner SE,et al. Left ventricular dysfunction among patients with embolic stroke of undetermined source and the effect of rivaroxaban vs aspirin: a subgroup analysis of the NAVIGATE ESUS randomized clinical trial[J]. JAMA Neurol,2021,78(12):1454-1460.

[19] Kasner SE,Swaminathan B,Lavados P,et al. Rivaroxaban or aspirin for patent foramen ovale and embolic stroke of undetermined source: a prespecified subgroup analysis from the NAVIGATE ESUS trial[J]. Lancet Neurol,2018,17(12):1053-1060.

[20] Eriksson BI,Borris LC,Friedman RJ,et al. Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty[J]. N Engl J Med,2008,358(26):2765-2775.

[21] Kakkar AK,Brenner B,Dahl OE,et al. Extended duration rivaroxaban versus short-term enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: a double-blind,randomised controlled trial[J]. Lancet,2008,372(9632):31-39.

[22] Lassen MR,Ageno W,Borris LC,et al. Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty[J]. N Engl J Med,2008,358(26):2776-2786.

[23] Turpie AG,Lassen MR,Davidson BL,et al. Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty (RECORD4): a randomised trial[J]. Lancet,2009,373(9676):1673-1680.

[24] Turpie AG,Lassen MR,Eriksson BI,et al. Rivaroxaban for the prevention of venous thromboembolism after hip or knee arthroplasty. Pooled analysis of four studies[J]. Thromb Haemost,2011,105(3):444-453.

[25] Rojas-Hernandez CM,Oo TH. Direct Oral Anticoagulants in the Prevention and Treatment of Venous Thromboembolism in Patients with Cancer: New Insights from Randomized Controlled Trials[J]. Drugs,2019,79(6):621-631.

[26] Walker AJ,Card TR,West J,et al. Incidence of venous thromboembolism in patients with cancer——A cohort study using linked United Kingdom databases[J]. Eur J Cancer,2013,49(6):1404- 1413.

[27] Young AM,Marshall A,Thirlwall J,et al. Comparison of an oral factor Xa inhibitor with low molecular weight heparin in patients with cancer with venous thromboembolism: results of a randomized trial (SELECT-D)[J]. J Clin Oncol,2018,36(20):2017-2023.

[28] Helms J,Tacquard C,Severac F,et al. High risk of thrombosis in patients with severe SARS-CoV-2 infection: a multicenter prospective cohort study[J]. Intensive Care Med,2020,46(6):1089-1098.

[29] Giannis D,Allen SL,Davidson A,et al. Thromboembolic outcomes of hospitalized COVID-19 patients in the 90-day post-discharge period: early data from the Northwell CORE-19 Registry[J]. Blood,2020,136(Suppl 1):33-34.

[30] Ramacciotti E,Barile Agati L,Calderaro D,et al. Rivaroxaban versus no anticoagulation for post-discharge thromboprophylaxis after hospitalisation for COVID-19 (MICHELLE): an open-label,multicentre,randomised,controlled trial[J]. Lancet,2022,399(10319):50-59.

[31] Bhatt DL,Eagle KA,Ohman EM,et al. Comparative determinants of 4-year cardiovascular event rates in stable outpatients at risk of or with atherothrombosis[J]. JAMA,2010,304(12):1350-1357.

[32] Connolly SJ,Eikelboom JW,Bosch J,et al. Rivaroxaban with or without aspirin in patients with stable coronary artery disease: an international,randomised,double-blind,placebo-controlled trial[J]. Lancet,2018,391(10117):205-218.

[33] Anand SS,Bosch J,Eikelboom JW,et al. Rivaroxaban with or without aspirin in patients with stable peripheral or carotid artery disease: an international,randomised,double-blind,placebo-controlled trial[J]. Lancet,2018,391(10117):219-229.

[34] 梁岩,龚泽彬,娄可佳,等. 利伐沙班与阿司匹林联用在中国稳定性心血管疾病患者中的有效性及安全性评价：COMPASS研究中国亚组分析[J]. 中华心血管病杂志,2021,49(9):873-879.

[35] Patel MR,Mahaffey KW,Garg J,et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation[J]. N Engl J Med,2011,365(10):883-891.

[36] Hindricks G,Potpara T,Dagres N,et al. 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): The Task Force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology (ESC) Developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC[J]. Eur Heart J,2021,42(5):373-498.

[37] Liu PY,Choi EK,Kim TS,et al. XaMINA: a real-world,prospective,observational study of treatment-na?ve patients treated with rivaroxaban for stroke prevention in atrial fibrillation in Asia[J]. Adv Ther,2022,39(7):3316-3333.

[38] Kim YH,Shim J,Tsai CT,et al. XANAP: A real-world,prospective,observational study of patients treated with rivaroxaban for stroke prevention in atrial fibrillation in Asia[J]. J Arrhythm,2018,34(4):418-427.

[39] Ikeda T,Ogawa S,Kitazono T,et al. Real-world outcomes of the Xarelto Post-Authorization Safety & Effectiveness Study in Japanese Patients with Atrial Fibrillation (XAPASS)[J]. J Cardiol,2019,74(1):60-66.

[40] López-López JA,Sterne JAC,Thom HHZ,et al. Oral anticoagulants for prevention of stroke in atrial fibrillation: systematic review,network meta-analysis,and cost effectiveness analysis[J]. BMJ,2017,359:j5058.

[41] Vaitkus PT,Barnathan ES. Embolic potential,prevention and management of mural thrombus complicating anterior myocardial infarction: a meta-analysis[J]. J Am Coll Cardiol,1993,22(4):1004-1009.

[42] Pastori D,Menichelli D,Cammisotto V,et al. Use of direct oral anticoagulants in patients with antiphospholipid syndrome: a systematic review and comparison of the international guidelines[J]. Front Cardiovasc Med,2021,8:715878.

[43] Zuily S,Cohen H,Isenberg D,et al. Use of direct oral anticoagulants in patients with thrombotic antiphospholipid syndrome: Guidance from the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis[J]. J Thromb Haemost,2020,18(9):2126-2137.

[44] Tektonidou MG,Andreoli L,Limper M,et al. EULAR recommendations for the management of antiphospholipid syndrome in adults[J]. Ann Rheum Dis,2019,78(10):1296-1304.

[45] Pengo V,Denas G,Zoppellaro G,et al. Rivaroxaban vs warfarin in high-risk patients with antiphospholipid syndrome[J]. Blood,2018,132(13):1365-1371.

相似文献/References:

[1]林莹 徐勇郭新红 刘昱圻.具有不同肌酐清除率水平的中国高龄非瓣膜性心房颤动患者应用利伐沙班的剂量选择研究[J].心血管病学进展,2019,(8):1176.[doi:10.16806/j.cnki.issn.1004-3934.2019.08.027]
　LIN Ying,XU Yong,GUO Xinhong,et al.Dose Selection of Rivaroxaban for Elderly Patients of Non-valvular Atrial Fibrillation with Different Levels of Creatinine Clearance in China[J].Advances in Cardiovascular Diseases,2019,(10):1176.[doi:10.16806/j.cnki.issn.1004-3934.2019.08.027]
[2]林莹,徐勇,郭新红,等.利伐沙班在心血管疾病中应用的临床进展[J].心血管病学进展,2020,(3):247.[doi:10.16806/j.cnki.issn.1004-3934.20.03.008]
　LIN Ying,XU Yong,GUO Xinhong,et al.Clinical Progress of Rivaroxaban in Cardiovascular Diseases[J].Advances in Cardiovascular Diseases,2020,(10):247.[doi:10.16806/j.cnki.issn.1004-3934.20.03.008]

更新日期/Last Update: 2022-12-26